Modulation of bevacizumab-induced toxicity for cultured human corneal fibroblasts

Eungkweon Kim, Sang Won Kang, Ji Yeon Kim, Kyung Min, Tae-im Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

PURPOSE. There are numerous reports describing the direct or indirect cellular toxicity of bevacizumab. In this study, we measured the direct toxicity of bevacizumab and determined its modulation by growth factors in cultured human corneal fibroblasts. METHODS. To measure the toxicity of bevacizumab and ranibizumab on corneal fibroblasts, lactate dehydrogenase (LDH) assays, fluorescence-activated cell sorting analyses, and Ki-67 staining were performed. The role of vascular endothelial growth factor (VEGF) in bevacizumab-related toxicity was evaluated after suppression of VEGF expression using small interfering RNA (siRNA) and VEGF receptor inhibition with SU1498. We evaluated alteration of cellular toxicity and anti-angiogenic function of bevacizumab with cotreatment of basic fibroblast growth factor (bFGF) or nerve growth factor (NGF) using human corneal fibroblasts and human umbilical vein endothelial cells (HUVECs). RESULTS. Application of bevacizumab induced cellular toxicity and delayed proliferation in a dose-dependent manner, but ranibizumab did not cause cellular damage. Elevated LDH observed after bevacizumab treatment was decreased by cotreatment with varying concentrations of fetal bovine serum. However, VEGF cotreatment, VEGF suppression, and VEGF receptor blocking did not influence bevacizumab-induced cell death. Cotreatment of cells with bFGF or NGF and 2 mg/mL bevacizumab reduced LDH elevation. Low-dose bFGF or NGF did not interfere with the antiangiogenic function of bevacizumab as measured by the tube formation assay and MTS (dimethylthiazol-diphenyltetrazolium bromide) assay of HUVECs. CONCLUSIONS. This study determined the cellular toxicity of bevacizumab and its modulation with bFGF or NGF. Cotreatment with bFGF or NGF with bevacizumab reduced cellular damage without interfering with the original antiangiogenic function. Some components of serum have a protective effect on bevacizumab-induced corneal epithelial change.

Original languageEnglish
Pages (from-to)3922-3931
Number of pages10
JournalInvestigative Ophthalmology and Visual Science
Volume54
Issue number6
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Fibroblasts
Fibroblast Growth Factor 2
Nerve Growth Factor
Vascular Endothelial Growth Factor A
L-Lactate Dehydrogenase
Vascular Endothelial Growth Factor Receptor
Human Umbilical Vein Endothelial Cells
Bevacizumab
Neurotrophin 3
Serum
Bromides
Small Interfering RNA
Intercellular Signaling Peptides and Proteins
Flow Cytometry
Cell Death
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

@article{0bf21b13f9d644e5a2c1f3cea785a061,
title = "Modulation of bevacizumab-induced toxicity for cultured human corneal fibroblasts",
abstract = "PURPOSE. There are numerous reports describing the direct or indirect cellular toxicity of bevacizumab. In this study, we measured the direct toxicity of bevacizumab and determined its modulation by growth factors in cultured human corneal fibroblasts. METHODS. To measure the toxicity of bevacizumab and ranibizumab on corneal fibroblasts, lactate dehydrogenase (LDH) assays, fluorescence-activated cell sorting analyses, and Ki-67 staining were performed. The role of vascular endothelial growth factor (VEGF) in bevacizumab-related toxicity was evaluated after suppression of VEGF expression using small interfering RNA (siRNA) and VEGF receptor inhibition with SU1498. We evaluated alteration of cellular toxicity and anti-angiogenic function of bevacizumab with cotreatment of basic fibroblast growth factor (bFGF) or nerve growth factor (NGF) using human corneal fibroblasts and human umbilical vein endothelial cells (HUVECs). RESULTS. Application of bevacizumab induced cellular toxicity and delayed proliferation in a dose-dependent manner, but ranibizumab did not cause cellular damage. Elevated LDH observed after bevacizumab treatment was decreased by cotreatment with varying concentrations of fetal bovine serum. However, VEGF cotreatment, VEGF suppression, and VEGF receptor blocking did not influence bevacizumab-induced cell death. Cotreatment of cells with bFGF or NGF and 2 mg/mL bevacizumab reduced LDH elevation. Low-dose bFGF or NGF did not interfere with the antiangiogenic function of bevacizumab as measured by the tube formation assay and MTS (dimethylthiazol-diphenyltetrazolium bromide) assay of HUVECs. CONCLUSIONS. This study determined the cellular toxicity of bevacizumab and its modulation with bFGF or NGF. Cotreatment with bFGF or NGF with bevacizumab reduced cellular damage without interfering with the original antiangiogenic function. Some components of serum have a protective effect on bevacizumab-induced corneal epithelial change.",
author = "Eungkweon Kim and Kang, {Sang Won} and Kim, {Ji Yeon} and Kyung Min and Tae-im Kim",
year = "2013",
month = "1",
day = "1",
doi = "10.1167/iovs.12-11287",
language = "English",
volume = "54",
pages = "3922--3931",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "6",

}

Modulation of bevacizumab-induced toxicity for cultured human corneal fibroblasts. / Kim, Eungkweon; Kang, Sang Won; Kim, Ji Yeon; Min, Kyung; Kim, Tae-im.

In: Investigative Ophthalmology and Visual Science, Vol. 54, No. 6, 01.01.2013, p. 3922-3931.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Modulation of bevacizumab-induced toxicity for cultured human corneal fibroblasts

AU - Kim, Eungkweon

AU - Kang, Sang Won

AU - Kim, Ji Yeon

AU - Min, Kyung

AU - Kim, Tae-im

PY - 2013/1/1

Y1 - 2013/1/1

N2 - PURPOSE. There are numerous reports describing the direct or indirect cellular toxicity of bevacizumab. In this study, we measured the direct toxicity of bevacizumab and determined its modulation by growth factors in cultured human corneal fibroblasts. METHODS. To measure the toxicity of bevacizumab and ranibizumab on corneal fibroblasts, lactate dehydrogenase (LDH) assays, fluorescence-activated cell sorting analyses, and Ki-67 staining were performed. The role of vascular endothelial growth factor (VEGF) in bevacizumab-related toxicity was evaluated after suppression of VEGF expression using small interfering RNA (siRNA) and VEGF receptor inhibition with SU1498. We evaluated alteration of cellular toxicity and anti-angiogenic function of bevacizumab with cotreatment of basic fibroblast growth factor (bFGF) or nerve growth factor (NGF) using human corneal fibroblasts and human umbilical vein endothelial cells (HUVECs). RESULTS. Application of bevacizumab induced cellular toxicity and delayed proliferation in a dose-dependent manner, but ranibizumab did not cause cellular damage. Elevated LDH observed after bevacizumab treatment was decreased by cotreatment with varying concentrations of fetal bovine serum. However, VEGF cotreatment, VEGF suppression, and VEGF receptor blocking did not influence bevacizumab-induced cell death. Cotreatment of cells with bFGF or NGF and 2 mg/mL bevacizumab reduced LDH elevation. Low-dose bFGF or NGF did not interfere with the antiangiogenic function of bevacizumab as measured by the tube formation assay and MTS (dimethylthiazol-diphenyltetrazolium bromide) assay of HUVECs. CONCLUSIONS. This study determined the cellular toxicity of bevacizumab and its modulation with bFGF or NGF. Cotreatment with bFGF or NGF with bevacizumab reduced cellular damage without interfering with the original antiangiogenic function. Some components of serum have a protective effect on bevacizumab-induced corneal epithelial change.

AB - PURPOSE. There are numerous reports describing the direct or indirect cellular toxicity of bevacizumab. In this study, we measured the direct toxicity of bevacizumab and determined its modulation by growth factors in cultured human corneal fibroblasts. METHODS. To measure the toxicity of bevacizumab and ranibizumab on corneal fibroblasts, lactate dehydrogenase (LDH) assays, fluorescence-activated cell sorting analyses, and Ki-67 staining were performed. The role of vascular endothelial growth factor (VEGF) in bevacizumab-related toxicity was evaluated after suppression of VEGF expression using small interfering RNA (siRNA) and VEGF receptor inhibition with SU1498. We evaluated alteration of cellular toxicity and anti-angiogenic function of bevacizumab with cotreatment of basic fibroblast growth factor (bFGF) or nerve growth factor (NGF) using human corneal fibroblasts and human umbilical vein endothelial cells (HUVECs). RESULTS. Application of bevacizumab induced cellular toxicity and delayed proliferation in a dose-dependent manner, but ranibizumab did not cause cellular damage. Elevated LDH observed after bevacizumab treatment was decreased by cotreatment with varying concentrations of fetal bovine serum. However, VEGF cotreatment, VEGF suppression, and VEGF receptor blocking did not influence bevacizumab-induced cell death. Cotreatment of cells with bFGF or NGF and 2 mg/mL bevacizumab reduced LDH elevation. Low-dose bFGF or NGF did not interfere with the antiangiogenic function of bevacizumab as measured by the tube formation assay and MTS (dimethylthiazol-diphenyltetrazolium bromide) assay of HUVECs. CONCLUSIONS. This study determined the cellular toxicity of bevacizumab and its modulation with bFGF or NGF. Cotreatment with bFGF or NGF with bevacizumab reduced cellular damage without interfering with the original antiangiogenic function. Some components of serum have a protective effect on bevacizumab-induced corneal epithelial change.

UR - http://www.scopus.com/inward/record.url?scp=84878809861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878809861&partnerID=8YFLogxK

U2 - 10.1167/iovs.12-11287

DO - 10.1167/iovs.12-11287

M3 - Article

VL - 54

SP - 3922

EP - 3931

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 6

ER -